New cocktail aims to tame Slow-Growing blood cancers
NCT ID NCT07609446
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase II trial will test a combination of pomalidomide, an anti-CD20 antibody, and prednisone as a first treatment for people with indolent (slow-growing) B-cell lymphomas. About 30 adults who have not had prior therapy will receive six cycles of the combo, followed by two years of maintenance. The main goal is to see how many patients respond, while also tracking side effects and how long the benefit lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pomalidomide, anti-CD20 antibody (a targeted immune therapy), and prednisone (a steroid)
What this could lead to
If successful, this could offer a new first-line treatment option for indolent B-cell lymphoma that may improve response rates and delay disease progression.
What could go wrong
This is a small, early-phase (Phase II) trial with only 30 participants, so results may not apply broadly. The combination may cause side effects like low blood counts or infections, and it is not a cure—patients will need ongoing maintenance therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••